Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03965494 · ClinicalTrials.gov registry record · Early Phase 1
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03965494 is a Early Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 10 participants.
The verdict
NCT03965494, a Early Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG BGB 324 (before surgery)
- DRUG BGB 324 (after surgery)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-01-02 |
| Est. Completion | 2023-10-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03965494
The ClinicalTrials.gov registry entry for NCT03965494 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BGB 324 (before surgery) is the first listed.
NCT03965494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03965494 about?
NCT03965494 is a clinical study titled "AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery". This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03965494?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-01-02. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT03965494?
The interventions under investigation include: BGB 324 (before surgery) (DRUG), BGB 324 (after surgery) (DRUG).
Who is sponsoring clinical trial NCT03965494?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.